Ovation Science Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Ovation Science's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been declining at an average rate of 32.2% per year.
Anahtar bilgiler
-1.2%
Kazanç büyüme oranı
9.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | -32.2% |
| Özkaynak getirisi | n/a |
| Net Marj | -625.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Ovation Science nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 1 | 0 |
| 31 Mar 24 | 0 | -1 | 1 | 0 |
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 30 Jun 23 | 0 | -1 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
| 30 Sep 22 | 0 | -2 | 1 | 0 |
| 30 Jun 22 | 0 | -2 | 1 | 0 |
| 31 Mar 22 | 0 | -2 | 1 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 1 | -1 | 1 | 0 |
| 31 Dec 20 | 1 | -1 | 1 | 0 |
| 30 Sep 20 | 1 | -1 | 1 | 0 |
| 30 Jun 20 | 1 | -1 | 1 | 0 |
| 31 Mar 20 | 1 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | -1 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -1 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Kaliteli Kazançlar: OVAT is currently unprofitable.
Büyüyen Kar Marjı: OVAT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: OVAT is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.
Büyüme Hızlandırma: Unable to compare OVAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: OVAT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Özkaynak Getirisi
Yüksek ROE: OVAT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.